Skip to Content
Full Title A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Protocol Number MIP-IB12B
clinicaltrials.gov https://clinicaltrials.gov/show/NCT00874614
Principal Investigator(s)
Division General Surgery
Status Active, not recruiting
Description

This clinical trial is designed to evaluate the effectiveness and collect additional safety information on Ultratrace® Iobenguane I 131 for the treatment of relapsed/refractory (to other treatment) malignant pheochromocytoma and paraganglioma.

The purpose of this trial is to test the use of Ultratrace® iobenguane I 131 as a treatment for pheochromocytoma and paraganglioma type cancer. This Phase II study will help determine primarily if using the drug reduces the amount of blood pressure medication being taken as a result of the cancer and secondarily to determine such things as the effectiveness of the study drug in treating the cancer, additional safety measures, and to assess if the drug helps the quality of life and use of pain medication. All subjects will receive an imaging dose with scans followed by two therapy doses that are given 3 months apart.

Other Clinical Trials in the Department of Surgery
webmaster@surgery.wisc.edu Copyright © 2016 The Board of Regents of the University of Wisconsin System